Souhaitez-vous accéder aux communiqués récents ?

Caplacizumab is a first-in-class anti-von Willebrand factor (vWF) Nanobody® in development for the treatment of acquired thrombotic thrombocytopenic purpura (TTP) Acquired TTP is an...

REGULATED INFORMATION   Caplacizumab on track to enter Phase III in acquired TTP, with Ablynx committed to lead commercialisation in Europe and the USA 4 Phase II clinical programmes...

GHENT, Belgium, Aug. 19, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will announce its half-year results for 2015 on Thursday 27 August 2015 at 7.00 am CET. The Ablynx...

REGULATED INFORMATION GHENT, Belgium, Aug. 14, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...

GHENT, Belgium, Aug. 4, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has administered the first dose in the Phase II STEADY study to evaluate the...

REGULATED INFORMATION GHENT, Belgium, July 31, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...

REGULATED INFORMATION GHENT, Belgium, July 29, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...

Builds on the original immuno-oncology collaboration started in 2014, significantly expanding the size and scope of the deal to include up to 12 additional Nanobody programmes Expanded deal...

REGULATED INFORMATION GHENT, Belgium, July 20, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...

REGULATED INFORMATION GHENT, Belgium, July 14, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...